Royalty Pharma Plc (RPRX)
63.86
+0.11
(+0.17%)
USD |
NASDAQ |
Oct 23, 16:00
63.84
-0.02
(-0.03%)
After-Hours: 20:00
Royalty Pharma Cash from Operations (Quarterly) : 715.25M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 715.25M |
| March 31, 2026 | 760.54M |
| December 31, 2025 | 832.14M |
| September 30, 2025 | 703.52M |
| June 30, 2025 | 426.97M |
| March 31, 2025 | 632.34M |
| December 31, 2024 | 745.77M |
| September 30, 2024 | 715.10M |
| June 30, 2024 | 662.15M |
| March 31, 2024 | 669.60M |
| December 31, 2023 | 777.28M |
| September 30, 2023 | 577.98M |
| June 30, 2023 | 607.82M |
| March 31, 2023 | 1.069B |
| December 31, 2022 | 569.93M |
| Date | Value |
|---|---|
| September 30, 2022 | 538.83M |
| June 30, 2022 | 574.95M |
| March 31, 2022 | 460.27M |
| December 31, 2021 | 489.96M |
| September 30, 2021 | 469.76M |
| June 30, 2021 | 532.24M |
| March 31, 2021 | 526.10M |
| December 31, 2020 | 565.67M |
| September 30, 2020 | 508.85M |
| June 30, 2020 | 504.09M |
| March 31, 2020 | 471.10M |
| December 31, 2019 | 478.43M |
| September 30, 2019 | 419.03M |
| June 30, 2019 | 336.88M |
| March 31, 2019 | 432.90M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Merck & Co., Inc. | 5.37B |
| Johnson & Johnson | 7.72B |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -216.51M |
| Cash from Financing (Quarterly) | -273.15M |
| Free Cash Flow | 612.50M |
| Free Cash Flow Per Share (Quarterly) | 0.8336 |
| Free Cash Flow to Equity (Quarterly) | 458.78M |
| Free Cash Flow to Firm (Quarterly) | 557.84M |
| Free Cash Flow Yield | 1.83% |